CervoMed (CRVO)

• Market cap: $18.4M
• 1 day: 0.00%
• 5 days: 19.25%
• 1 month: -76.87%
• 3 months: -86.76%
• 6 months: -89.58%
• Year to date: -72.13%
• 1 year: -67.63%
• 5 years: -90.10%
• 10 years: -99.93%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Employees: 8

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

275% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 4

29% more funds holding

Funds holding: 38 [Q2] → 49 (+11) [Q3]

20% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 10

0.62% more ownership

Funds ownership: 41.87% [Q2] → 42.49% (+0.62%) [Q3]

13% less capital invested

Capital invested by funds: $59.1M [Q2] → $51.2M (-$7.96M) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 438% upside
• Avg. target: $29 1,178% upside
• High target: $45 1,918% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Canaccord Genuity Sumant Kulkarni 22% 1-year accuracy 7 / 32 met price target	438% upside $12	Buy Maintained	11 Dec 2024
Roth MKM Boobalan Pachaiyappan 0% 1-year accuracy 0 / 4 met price target	1,918% upside $45	Buy Initiated	5 Dec 2024